New horizons in osteoporosis therapies.

Abstract

Efficient therapies are available for the treatment of osteoporosis, however, there are still unmet needs. Anti-resorptive therapies only increase bone mineral density to a certain extent and reduce the risk of non-vertebral fractures by 20%, only one anabolic option is available-the effect of which levels off over time, and the evidence for combination therapy targeting both resorption and formation is limited. The current review will focus on emerging treatments of osteoporosis with the potential of enhanced anabolic effects (romosozumab and abaloparatide) or uncoupling of resorption and formation (odanacatib and romosozumab) as well as the effect of combination therapy.

• Authors: Torben Harsløf, Bente L Langdahl
• Journal: Current opinion in pharmacology (Curr Opin Pharmacol) Vol. 28 Pg. 38-42 (06 2016) ISSN: 1471-4973 [Electronic] England
• PMID: 26989807 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2016 Elsevier Ltd. All rights reserved.

Chemical References

• Antibodies, Monoclonal
• Bone Density Conservation Agents

Topics

• Animals
• Antibodies, Monoclonal (administration & dosage, pharmacology, therapeutic use)
• Bone Density (drug effects)
• Bone Density Conservation Agents (administration & dosage, pharmacology, therapeutic use)
• Drug Design
• Drug Therapy, Combination
• Humans
• Osteoporosis (drug therapy, physiopathology)